Scarica l'app Stockscreener
162.32
3.42%
-5.74
Dopo l'orario di chiusura:
164.39
2.07
+1.28%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ILMN Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$168.06
Aprire:
$167.58
Volume 24 ore:
2.05M
Relative Volume:
1.26
Capitalizzazione di mercato:
$24.56B
Reddito:
$4.39B
Utile/perdita netta:
$853.00M
Rapporto P/E:
29.46
EPS:
5.5097
Flusso di cassa netto:
$556.00M
1 W Prestazione:
-0.39%
1M Prestazione:
+16.72%
6M Prestazione:
+25.87%
1 anno Prestazione:
+97.35%
Intervallo 1D:
$160.60
$168.62
Intervallo di 1 settimana:
$159.48
$177.22
Portata 52W:
$82.44
$177.22
Illumina Inc Stock (ILMN) Company Profile
Nome
Illumina Inc
Settore
Industria
Telefono
(858) 202-4500
Indirizzo
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN vs TMO, DHR, IDXX, A, WAT
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
162.32 | 25.43B | 4.39B | 853.00M | 556.00M | 5.5097 |
TMO
Thermo Fisher Scientific Inc
|
472.80 | 179.13B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
184.30 | 132.10B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.16 | 44.55B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
135.44 | 39.08B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
365.36 | 36.96B | 3.77B | 449.25M | 240.68M | 7.8556 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-12 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-07-11 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-04 | Reiterato | Citigroup | Neutral |
| 2025-02-28 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-02-10 | Downgrade | Barclays | Equal Weight → Underweight |
| 2025-02-07 | Downgrade | TD Cowen | Buy → Hold |
| 2024-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2024-11-12 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-10-17 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-08-28 | Aggiornamento | Argus | Hold → Buy |
| 2024-08-16 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2024-08-14 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2024-08-14 | Aggiornamento | TD Cowen | Hold → Buy |
| 2024-07-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-06-03 | Ripresa | Jefferies | Hold |
| 2024-01-16 | Downgrade | HSBC Securities | Buy → Hold |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-12-18 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2023-12-15 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-14 | Iniziato | Stephens | Overweight |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-12-12 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-12-11 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-11-10 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-09-28 | Iniziato | Bernstein | Underperform |
| 2023-07-05 | Ripresa | JP Morgan | Neutral |
| 2023-01-25 | Downgrade | Argus | Buy → Hold |
| 2023-01-05 | Iniziato | Scotiabank | Sector Perform |
| 2022-12-12 | Downgrade | Citigroup | Neutral → Sell |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-10-04 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-09-28 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2022-08-25 | Iniziato | Credit Suisse | Neutral |
| 2022-07-13 | Downgrade | Barclays | Equal Weight → Underweight |
| 2022-01-18 | Aggiornamento | Stifel | Hold → Buy |
| 2022-01-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-01-07 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-06 | Ripresa | Piper Sandler | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-06-01 | Aggiornamento | Evercore ISI | Underperform → In-line |
| 2021-03-31 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2021-03-31 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2021-03-03 | Iniziato | Barclays | Underweight |
| 2020-12-22 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-12-17 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-10-13 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-09-30 | Iniziato | Atlantic Equities | Overweight |
| 2020-09-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2020-09-22 | Downgrade | Stifel | Buy → Hold |
| 2020-09-22 | Downgrade | UBS | Buy → Neutral |
| 2020-09-21 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-09-21 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-08-07 | Downgrade | Evercore ISI | In-line → Underperform |
| 2020-08-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-04-24 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-01-08 | Iniziato | Wells Fargo | Underweight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-10-25 | Iniziato | Guggenheim | Buy |
Mostra tutto
Illumina Inc Borsa (ILMN) Ultime notizie
Illumina Inc. stock underperforms Friday when compared to competitors - MarketWatch
Illumina (Nasdaq: ILMN) Form 144 lists proposed sale by trust - Stock Titan
Illumina Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Illumina (ILMN) chief people officer sells 784 shares in open market - Stock Titan
What is multiomics? A simple guide to the future of biology - Illumina
Is Grail Stock a Bad-News Buy After Its Recent Pullback? - The Motley Fool
Illumina Inc. stock (US4523271090): shares edge higher on Nasdaq amid focus on sequencing demand and - AD HOC NEWS
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
Illumina jumps as bullish analyst note extends optimism around clinical sequencing momentum - Quiver Quantitative
ILMN Stock Jumps 98.7% in a Year: What's Powering the Surge? - TradingView
Illumina Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Illumina, Inc. Hits New 52-Week High of $165.93, Up 54% - Markets Mojo
Illumina, Inc. Hits New 52-Week High at USD 165.37 - Markets Mojo
Illumina, Inc. Hits New 52-Week High of $158.78, Up 48.7% - Markets Mojo
[144] ILLUMINA, INC. SEC Filing - Stock Titan
Frances Arnold reports proposed sale of 5,000 shares | ILMN SEC FilingForm 144 - Stock Titan
IDT partners with Illumina on oncology research workflow - Investing.com UK
Illumina Insider Sold Shares Worth $107,042,631, According to a Recent SEC Filing - Moomoo
Integrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster Insights - BioSpace
Insider Sell: Scott Davies Sells Shares of Illumina Inc (ILMN) - GuruFocus
Why (ILMN) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Illumina director Keith Meister sells $107 million in shares By Investing.com - Investing.com Australia
Illumina director Keith Meister sells $107 million in shares - Investing.com
Corvex funds tied to Illumina (ILMN) log 669,596-share stock sale - Stock Titan
Illumina VP, chief accounting officer sells $305,150 in ILMN stock By Investing.com - Investing.com Australia
Guggenheim raises Illumina stock price target on clinical market strength - Investing.com UK
Illumina VP, chief accounting officer sells $305,150 in ILMN stock - Investing.com
Illumina (ILMN) legal chief sells 615 shares in open market trade - Stock Titan
Illumina Inc. stock (US4523271090): New oncology research workflows and MRD solution highlight innov - AD HOC NEWS
Illumina (ILMN) chief accounting officer sells 2,000 company shares in open market - Stock Titan
Hunting for hidden clues in the human genome’s “dark regions” - Illumina
Integrated DNA Technologies (DHR) Partners with Illumina for Enh - GuruFocus
IDT partners with Illumina on oncology research workflow By Investing.com - Investing.com South Africa
Guggenheim Maintains Illumina(ILMN.US) With Buy Rating, Raises Target Price to $180 - Moomoo
Guggenheim raises Illumina stock price target on clinical market strength By Investing.com - Investing.com Australia
Illumina, Inc. (ILMN) Stock Analysis: Understanding the Growth Potential Amidst a Robust Market Cap - DirectorsTalk Interviews
Illumina Inc. stock (US4523271090): shares track Nasdaq ahead of next catalysts - AD HOC NEWS
Here's why Illumina (ILMN) is a strong momentum stock - MSN
Illumina Oncology Launches Put Product Depth Against Rapid Share Price Gains - Yahoo Finance Singapore
Illumina Inc. stock (US4523271090): insider share sale and new MRD kit draw investor focus - AD HOC NEWS
Why Illumina (ILMN) is a top momentum stock for the long term - MSN
Illumina Ducks DNA Sequence Rival's Antitrust Suit, For Now - Law360
Corvex Management LP sells multiple ILMN blocks (ILMN) in May 2026 - Stock Titan
lllumina Beats Rival’s DNA-Sequencing Tool Monopolization Claims - news.bloombergtax.com
Illumina, Inc. Hits Day High with Strong 5.68% Intraday Surge - Markets Mojo
Illumina (NASDAQ: ILMN) director sold 1,500 shares under 10b5-1 plan - Stock Titan
Illumina (ILMN) director Keith Meister updates 3.5M indirect share position - Stock Titan
Illumina launches new sequencing tech for molecular residual disease research - MSN
Illumina Inc. stock (US4523271090): shares near 12-month high after new automation launch - AD HOC NEWS
Illumina and SPT Labtech on fire with new collaboration - Business Weekly
Assessing Illumina (ILMN) Valuation After Its New MRD Research Solution Expands Oncology Offering - Sahm
Illumina Inc Azioni (ILMN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.22%
2.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):